Claims for Patent: 4,647,532

Summary for Patent: 4,647,532

Title:	Method for determination of hydrogen peroxide by chemiluminescence analysis
Abstract:	A method for determination of hydrogen peroxide by chemiluminescence analysis which consists of reacting a sample containing hydrogen peroxide with an oxidizable non-fluorescent substance in the presence of an oxidizing catalyst to convert the non-fluorescent substance to a fluorescent substance, reacting the fluorescent substance with an oxalic acid di-ester and hydrogen peroxide in the presence of an inhibitor which inactivates the oxidizing catalyst, and then measuring the amount of light emission produced to determine the amount of hydrogen peroxide contained in the sample. Determination and enzyme immunoassay for a component other than hydrogen peroxide in a sample from living body and evaluation of bactericidal activity in phagocytosis of leukocytes by utilizing this method are also disclosed.
Inventor(s):	Watanabe; Haruo (Ayabe, JP), Mitsuhida; Noboru (Tsuruga, JP), Andoh; Makoto (Ohtsu, JP), Matsumoto; Hakuji (Ohtsu, JP)
Assignee:	Toyo Boseki Kabushiki Kaisha (Osaka, JP)
Application Number:	06/714,743
Patent Claims:	1. A method for determination of hydrogen peroxide by chemiluminescence analysis which comprises the steps of (a) reacting a sample containing hydrogen peroxide with an oxidizable non-fluorescent substance in the presence of an oxidizing catalyst in an aqueous reaction system to convert the non-fluorescent substance to a fluorescent substance, (b) reacting the fluorescent substance with an oxalic acid di-ester and hydrogen peroxide in the presence of an inhibitor for the oxidizing catalyst whereby the oxidizing catalyst is inactivated, and then (c) measuring the amount of light emitted from reaction (b) to determine the amount of hydrogen peroxide contained in the sample. 2. A method according to claim 1, wherein the oxidizable non-fluorescent substance is a member selected from the group consisting of leucofluorescein, 2',7'-dichlorofluoresceine-diacetate, leucorhodamin, leucoeosin, homovanillic acid, p-cresol, 3-(p-hydroxyphenyl)propionic acid and thyramine and is present in an amount of 0.001 to 5 mM in the aqueous reaction system. 3. A method according to claim 1, wherein the oxidizing catalyst is a member selected from the group consisting of peroxidase, microperoxidase, myeloperoxidase, hemin, hematine, catalase and potassium ferricyanide. 4. A method according to claim 1, wherein the oxalic acid di-ester is a member selected from the group consisting of bis(2,4,6-trichlorophenyl)oxalate and bis(2,4-dinitrophenyl)oxalate and is present in an amount of 0.1 to 50 mM in the reaction thereof with the fluorescent substance. 5. A method according to claim 1, wherein hydrogen peroxide is present in an amount of 0.1 to 50 mM in the reaction thereof with the fluorescent substance. 6. A method according to claim 1, wherein the reaction of hydrogen peroxide in the sample with the nonfluorescent substance is performed at a temperature of about 20.degree. to 30.degree. C. at pH 5 to 9. 7. A method according to claim 1, wherein a cyclodextrin is added to the aqueous reaction system in an amount of 10.sup.-5 to 10.sup.-1 M. 8. A method according to claim 1, wherein zinc sulfate hepta hydrate is added to the aqueous reaction system to produce a final concentration of zinc sulfate hepta hydrate of about 0.04 mg/ml. 9. A method according to claim 1, wherein the reaction of the fluorescent substance with the oxalic acid di-ester and hydrogen peroxide is performed at a temperature of about 20.degree. to 40.degree. C. at pH of 8 to 12. 10. A method according to claim 1, wherein the reaction of the fluorescent substance with the oxalic acid di-ester and hydrogen peroxide is performed in an organic solvent containing water wherein the organic solvent is the inhibitor for the oxidizing catalyst. 11. A method according to claim 10, wherein the organic solvent is a member selected from the group consisting of ethyl acetate, acetone, acetonitrile and a mixture thereof. 12. A method according to claim 1, wherein the inhibitor is a member selected from the group consisting of potassium cyanide, sodium cyanide, sodium azide, sulfides, fluorides, hydroxyphenylhydrazine, 2,3-dimercaptopropanol and organic solvent. 13. A method according to claim 12, wherein the organic solvent is a member selected from the group consisting of ethyl acetate, acetonitrile, ethanol and acetone. 14. A method according to claim 1, wherein hydrogen peroxide in the sample is derived from a component of a body fluid. 15. A method according to claim 14, wherein the body fluid is blood, urine, saliva or tears. 16. A method according to claim 1, wherein the sample is obtained from a reaction mixture of enzyme immunoassay, and hydrogen peroxide in the sample is derived from a physiologically active substance to be determined by the enzyme immunoassay in an immunological reaction for quantitative production of hydrogen peroxide from the physiologically active substance. 17. A method according to claim 16, wherein the physiologically active substance is selected from the group consisting of peptide hormones, steroid hormones, fetal proteins, immunoglobulins, antiviral antibodies developed in various infections and autoantibodies developed in collagen disease. 18. A method according to claim 16, wherein the enzyme immunoassay is performed by subjecting the physiologically active substance in a body fluid sample to an immunological reaction by using an enzyme which is capable of formation of hydrogen peroxide as a labelling enzyme, adding a substrate for the enzyme to form hydrogen peroxide, reacting hydrogen peroxide thus formed with the oxidizable non-fluorescent substance in the presence of the oxidizing catalyst to convert the non-fluorescent substance into the fluorescent substance, reacting the fluorescent substance with the oxalic acid di-ester and hydrogen peroxide in the presence of an inhibitor for the oxidizing catalyst whereby the oxidizing catalyst is inactivated and then determining the amount of light emitted from the reacting of the fluorescent substance with the oxalic acid di-ester and hydrogen peroxide. 19. A method according to claim 18, wherein the oxidizing catalyst is peroxidase. 20. A method according to claim 18, wherein the enzyme which is capable of formation of hydrogen peroxide is a member selected from the group consisting of glucose oxidase, cholesterol oxidase, choline oxidase and an amino acid oxidase. 21. A method according to claim 20, wherein the enzyme is glucose oxidase. 22. A method according to claim 1, wherein the sample is a suspension of leukocytes showing phagocytosis. 23. A method for determination of a component of a body fluid by chemiluminescence analysis which comprises the steps of (a) reacting a component in a sample from a body fluid or a substance formed by an enzymatic reaction of an enzyme in a sample from a body fluid with an oxidase to form hydrogen peroxide, (b) reacting the hydrogen peroxide thus formed with an oxidizable non-fluorescent substance in the presence of an oxidizing catalyst in an aqueous reaction system to convert the non-fluorescent substance to a fluorescent substance, (c) reacting the fluorescent substance with an oxalic acid di-ester and hydrogen peroxide in the presence of an inhibitor for the oxidizing catalyst whereby the oxidizing catalyst is inactivated, and then (d) measuring the amount of light emitted from reaction (c) to determine the amount of the component of the enzymatic activity in the sample from the body fluid. 24. A method according to claim 23, wherein the sample from the body fluid is blood, urine, saliva or tears. 25. A method according to claim 23, wherein the component of the body fluid is selected from the group consisting of uric acid, cholesterols, glucose, creatinine, polyamines, triglycerides, lactates, pyruvates and fatty acids. 26. A method according to claim 23, wherein the inhibitor is a member selected from the group consisting of potassium cyanide, sodium cyanide, sodium azide, sulfides, fluorides, hydroxyphenylhydrazine, 2,3-dimercaptopropanol and organic solvents. 27. A method according to claim 23, wherein the organic solvent is a member selected from the group consisting of ethyl acetate, acetonitrile, ethanol and acetone. 28. A method for determination of a physiologically active substance which comprises the steps of (a) performing enzyme immunoassay of the physiologically active substance in a reaction mixture using peroxidase as a labeling enzyme, (b) obtaining a sample of the reaction mixture of the enzyme immunoassay, (c) reacting the sample with hydrogen peroxide and oxidizable non-fluorescent substance in an aqueous reaction system to convert the non-fluorescent substance to a fluorescent substance, (d) reacting the fluorescent substance with an oxalic acid di-ester and hydrogen peroxide in the presence of an inhibitor for peroxidase whereby the peroxidase is inactivated, and then (e) measuring the amount of light emitted from reaction (d) to determine the amount of the physiologically active substance. 29. A method according to claim 28, wherein the physiologically active substance is selected from the group consisting of peptide hormones, steroid hormones, fetal proteins, immunoglobulins, antiviral antibodies developed in various infections and autoantibodies developed in collagen disease. 30. A method according to claim 28, wherein the inhibitor is a member selected from the group consisting of potassium cyanide, sodium cyanide, sodium azide, sulfides, fluorides, hydroxyphenylhydrazine, 2,3-dimercaptopropanol and organic solvent. 31. A method according to claim 30, wherein the organic solvent is a member selected from the group consisting of ethyl acetate, acetonitrile, ethanol and acetone.

Details for Patent 4,647,532

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246	07/20/1983		2004-03-21